Table 3.

Clinical characteristics of six cases of coexisting AAV and HIT, including this case

Literature	Age	Sex	Type of ANCA	Organ injury	Treatment for AAV	Onset of HIT	Type of heparin	Thrombotic event	Treatment for HIT
Roe et al. [31].	65	M	PR3	Crescentic glomerulonephritis Pulmonary hemorrhage	mPSL pulse, PSL, CY Hemodialysis	9 days after the start of hemodialysis	Unfractionated heparin	Deep venous thrombosis	Danaparoid
Kaneda et al. [32].	91	F	MPO	Kidney dysfunction Pulmonary hemorrhage	mPSL pulse, PSL, Hemodialysis	13 days after the start of hemodialysis	Unfractionated heparin	N/A	Argatroban
Mandai et al. [33].	40	M	MPO	Crescentic glomerulonephritis Interstitial pneumonia	mPSL pulse, PSL, CY, PE, Hemodialysis	5 days after the start of hemodialysis	Unfractionated heparin	Clotting in hemodialysis catheter	Argatroban
Thong et al. [34].	71	M	PR3	Kidney dysfunction	mPSL pulse, PSL, CY, Hemodialysis	15 days after the start of hemodialysis	Unfractionated heparin	Circuit and catheter clotted	Argatroban
Nonaka et al. [35].	87	F	MPO	Kidney dysfunction	PSL Hemodialysis	8 days after the start for prevention of deep vein thrombosis	Unfractionated heparin	Deep venous thrombosis	Argatroban
This case	76	M	MPO	Crescentic glomerulonephritis Interstitial pneumonia	mPSL pulse, PSL, CY Hemodialysis	14 days after the start of hemodialysis	Unfractionated heparin	cerebral infarction Clotting in hemodialysis catheter	Aargatroban

ANCA Anti-neutrophil cytoplasmic antibody, AAV anti-neutrophil cytoplasmic antibody-associated vasculitis, HIT heparin-induced thrombocytopenia, PR3 proteinase 3, MPO myeloperoxidase, mPSL methylprednisolone, PSL prednisolone, CY cyclophosphamide, PE plasma exchange